Nanobody-based polyvinyl alcohol beads as antifouling adsorbents for selective removal of tumor necrosis factor-α

Wang, Lichun; Ding, Yu; Li, Nan; Chai, Yamin; Li, Qiyu; Du, Yunzheng; Hong, Zhangyong; Ou, Lailiang

doi:10.1016/j.cclet.2021.12.087

Cited by 8 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mere 2 g of NbC21-sorbent is capable of removing 93% of TNF-α from a patient’s plasma within 90 min. In comparison to similar cytokine removal products, such as the adsorbent (∼190 g) used by Seredych et al and the immunosorbent (∼10 g) prepared by Wang et al, our NbC21-sorbent offers a distinct dosing advantage. , By utilizing high-affinity ligands to ensure performance, reduced dosages may lead to cost savings and facilitate flexible combinations of different cytokine immunosorbents, potentially enhancing therapeutic efficacy and expanding clinical scenarios. , …”

Section: Resultsmentioning

confidence: 99%

“…In comparison to similar cytokine removal products, such as the adsorbent (∼190 g) used by Seredych dosing advantage. 35,36 By utilizing high-affinity ligands to ensure performance, reduced dosages may lead to cost savings and facilitate flexible combinations of different cytokine immunosorbents, potentially enhancing therapeutic efficacy and expanding clinical scenarios. 37,38 3.5.…”

Section: Comparison Of Dynamic Adsorption Capacities Against Tnf-αmentioning

confidence: 99%

See 1 more Smart Citation

Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α

Chen,

Yao,

Huang

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Removing the overexpressed TNF-α by hemoperfusion positively affects clinical treatments for diseases such as autoimmune disease and sepsis. However, clearance ratios of adsorbents targeting TNF-α were limited by the extremely low concentration of TNF-α (mostly <1000 ng/L in sepsis) and hydrophobic interactions. In this work, biparatopic nanobodies (NbC21) with a high affinity of 19.9 pM, which bind to two distinct sites of TNF-α, were constructed as high-affinity ligands for the immunosorbent. The theoretical maximum adsorption capacity estimated from the Langmuir isotherm was up to 18.22 mg/g gel. The prepared immunosorbent (NbC21-sorbent) had an outstanding TNF-α clearance ratio of approximately 96% during the dynamic adsorption test, with a sorbent-to-serum ratio of 1:1000. Additionally, it demonstrated favorable hemocompatibility and a prolonged storage capability. The results indicated that the biparatopic nanobody immunosorbent exhibited significant potential for clinical applications as it met the stringent criteria for both efficacy and safety.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Comparison Of Dynamic Adsorption Capacities Against Tnf-αmentioning

confidence: 99%

Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α

Chen,

Yao,

Huang

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Cytokines produced by COVID‐19 infection play a crucial role in the aetiology and pathophysiology of the disease, especially the overproduction of pro‐inflammatory cytokines such as IL‐1, IL‐6, IL‐12, IFN‐γ and TNF‐α, 37 , 38 , 39 and the levels of these cytokines correlate with disease prognosis. 40 , 41 However, the serological cytokine profile of convalescent COVID‐19 patients remains unclear.…”

Section: Resultsmentioning

confidence: 99%

Post‐hospitalization rehabilitation alleviates long‐term immune repertoire alteration in COVID‐19 convalescent patients

et al. 2023

View full text Add to dashboard Cite

The global pandemic of Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is an once‐in‐a‐lifetime public health crisis. Among hundreds of millions of people who have contracted with or are being infected with COVID‐19, the question of whether COVID‐19 infection may cause long‐term health concern, even being completely recovered from the disease clinically, especially immune system damage, needs to be addressed. Here, we performed seven‐chain adaptome immune repertoire analyses on convalescent COVID‐19 patients who have been discharged from hospitals for at least 6 months. Surprisingly, we discovered lymphopenia, reduced number of unique CDR3s, and reduced diversity of the TCR/BCR immune repertoire in convalescent COVID‐19 patients. In addition, the BCR repertoire appears to be activated, which is consistent with the protective antibody titres, but serological experiments reveal significantly lower IL‐4 and IL‐7 levels in convalescent patients compared to those in healthy controls. Finally, in comparison with convalescent patients who did not receive post‐hospitalization rehabilitation, the convalescent patients who received post‐hospitalization rehabilitation had attenuated immune repertoire abnormality, almost back to the level of healthy control, despite no detectable clinic demographic difference. Overall, we report the potential long‐term immunological impairment for COVID‐19 infection, and correction of this impairment via post‐hospitalization rehabilitation may offer a new prospect for COVID‐19 recovery strategy.

show abstract

“…Schematic illustration of the synthesis of hemoperfusion adsorbent using synthetic polymer materials: (a) PS adsorbents with high specific surface area and high mesoporosity for bilirubin removal (Copyright 2017, Taylor & Francis), (b) PVA immunosorbent with Nb ligand for TNF-α scavenging (Copyright 2022, Elsevier), (c) ion-exchange resin adsorbent for LDL clearence (Copyright 2009, IOP Science), and (d) PEI fiber membrane for bilirubin adsorption (Copyright 2018, Elsevier).…”

Section: Hemoperfusion Adsorbent Materialsmentioning

confidence: 99%

“…Blood purification materials such as activated carbon, polysaccharides, − and synthetic resins , are widely used because of their large specific surface area, excellent biocompatibility, ease of synthesis, and large exchange capacity. The development of new adsorbent materials with various continues apace, such as new carbon materials, magnetic nanoparticles, natural and synthetic polymers, composite materials, , and renewable stimuli-responsive adsorbents , has been applied to the removal of harmful substances from blood. These new materials exhibit greatly improved adsorption performance and excellent biocompatibilityan important criterion for evaluating hemoperfusion adsorbents.…”

Section: Introductionmentioning

confidence: 99%

An Evolutionary Review of Hemoperfusion Adsorbents: Materials, Preparation, Functionalization, and Outlook

Guo,

Jiang,

Guo

et al. 2024

ACS Biomater. Sci. Eng.

Self Cite

View full text Add to dashboard Cite

Accumulation of pathogenic factors in the blood may cause irreversible damage and may even be life-threatening. Hemoperfusion is an effective technique for eliminating pathogenic factors, which is widely used in the treatment of various diseases including liver failure, renal failure, sepsis, and others. Hemoperfusion adsorbents are crucial in this process as they specifically bind and remove the target pathogenic factors. This review describes the development of hemoperfusion adsorbents, detailing the different properties exhibited by inorganic materials, organic polymers, and new materials. Advances in natural and synthetic polymers and novel materials manufacturing techniques have driven the expansion of hemoperfusion adsorbents in clinical applications. Stimuli-responsive (smart responsive) adsorbents with controllable molecular binding properties have many promising and environmentally friendly biomedical applications. Knowledge gaps, future research directions, and prospects for hemoperfusion adsorbents are discussed.

show abstract

Nanobody-based polyvinyl alcohol beads as antifouling adsorbents for selective removal of tumor necrosis factor-α

Cited by 8 publications

References 29 publications

Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α

Biparatopic Nanobody-Based Immunosorbent for the Highly Selective Elimination of Tumor Necrosis Factor-α

Post‐hospitalization rehabilitation alleviates long‐term immune repertoire alteration in COVID‐19 convalescent patients

An Evolutionary Review of Hemoperfusion Adsorbents: Materials, Preparation, Functionalization, and Outlook

Contact Info

Product

Resources

About